An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

Teladoc Health has partnered with Eli Lilly's LillyDirect and pharmacy provider GiftHealth to expand access to Zepbound, a GLP-1 drug prescribed for weight loss. The partnership allows Teladoc ...

Eligible Teladoc Health members, if prescribed Zepbound ® by their Teladoc Health provider for an on-label indication, can have single-use Zepbound ® vials delivered directly to their home. Teladoc ...